Topical Webinars

NWABR provides and supports a series of one-off webinars on topical subjects for the biomedical research community. These webinars are provided as a service to the community in recognition of the importance of providing timely information on emerging topics. The following are the planned upcoming webinars:

NWABR in partnership with States United for Biomedical Research is presenting the following one-off webinar:

HIV Vaccines: Progress in 2023 and What the Future Holds

One off live webinar - Thursday, August 17, 2023 @ 11am Pacific/2pm Eastern

Dr Nancy Haigwood, PhD

Professor, Division of Pathobiology & Immunology and immediate past Director of the Oregon National Primate Research Center at OHSU

Since 1986 Dr Haigwood has focused her research on HIV, a virus for which there is still not an effective vaccine.

Her laboratory has shown that human antibodies that block HIV in the lab can clear infection in animal models, when given days after the infection.

These findings are helping to guide clinical trials for antibodies as therapies to prevent HIV and AIDS in Children.

Dr. Haigwood has been an advocate for HIV AIDS Community Support and Education, serving for 8 years and a member of the Cascade AIDS Project Advisory Board. Dr. Haigwood was elected to the American Academy of Microbiology in 2014, and in 2022 she was the recipient of the Buster and Nancy D. Alvord Award in recognition of her commitment to openness and transparency in research.

In this presentation Dr. Haigwood will:

• Provide a brief summary of vaccines and how they have saved lives.

• Provide HIV’s brief history since the 1980’s

• Explain what makes HIV such a difficult virus for vaccine development, and

• Discuss three major breakthroughs that offer hope for future vaccines.

Past Webinars

Are you ready to conduct Gene Therapy Research?

One off live webinar – Thursday, November 17, 2022 @ 11am Pacific/2pm Eastern

In response to requests from our stakeholder community NWABR and SUBR have brought together institutional biosafety committee (IBC) and institutional review board (IRB) professionals who will provide an introduction into genetically engineered therapies and how the development of such therapies are impacting the work of IBCs and IRBs. In this webinar they will take a look at the basics of conducting human gene therapy research, requirements for IBC and IRB review, they will share examples of how these two committees have to work together for effective research oversight, and ultimately prepare you and your site to be ready when the next human gene therapy trial comes along.

Learning Objectives:

Define the basic regulations and guidelines governing IBCs and IRBs in relation to gene therapy research
Explain the role of the IBC and how their oversight is different than that of the IRB
Provide examples of the importance of effective shared oversight from these committees
Outline key takeaways to prepare your research site to participate in this growing field of research

Presenters

Bios

Christopher Doyle, PhD

Chris Doyle is Director of IBC Services and an IBC Chair at WCG, roles in which he works with clinical trial sites, sponsors, and CROs to ensure research involving human gene transfer is conducted safely. Prior to joining WCG in early 2018, Chris was a research fellow at the Albert Einstein College of Medicine (Bronx, NY), where he explored novel mechanisms of antibody activity against Streptococcus pneumoniae.

Dr. Doyle received his BA in Biology from Assumption College (Worcester, MA) in 2008 and his PhD in Molecular Genetics and Microbiology from Stony Brook University (Stony Brook, NY) in 2014, where he studied the pathogenesis of Francisella tularensis in a high containment Biosafety Level 3 laboratory. Dr. Doyle has authored a number peer-reviewed publications describing his past research, frequently speaks about gene therapy, biosafety, and IBCs, and is a member of the American Society for Microbiology (ASM) and the American Biological Safety Association (ABSA).

James Riddle, BA, MCSE, CIP, CPIA

James Riddle is the Vice President Research Services & Strategic Consulting for Advarra where he employs his extensive experiences managing large research operations, technology, and research compliance teams to support our client’s research programs and grow Advarra worldwide.

In addition to leading Advarra’s Biosafety Service, Biostatistical Service, GPStm Service, and strategic consulting teams; Mr. Riddle also serves on the Board of the Northwest Association for Biomedical Research (NWABR); as Chair of the Site Accreditation and Standards Initiative (SASI) Accreditation Council; as member of the CTTI and MRCT Steering Committees; as editorial board member for IRB Advisor; as well as a faculty member, mentor, and regular speaker for Public Responsibility in Medicine and Research (PRIM&R).

Prior to joining Advarra, Mr. Riddle served as a leader of the human subject protection and animal care and use program at the Fred Hutchinson Cancer Research Center, one of the nation’s largest independent cancer research centers. In addition, he has previously served as an AAHRPP site visitor and was the Vice President of Operations and Director of Technology at another large central IRB. His expertise includes multi-national research operations and compliance, implementation of research technology solutions, computer software validation, and management of large IRB, IACUC, and IBC systems.

Mr. Riddle has a bachelor’s degree in accounting with an emphasis in computer science from Western Washington University, College of Business and Economics.

R. Bert Wilkins, J.D., M.H.A., C.I.P.

R. Bert Wilkins is one of the Regulatory Chair Directors WCG Institutional Review Board (WCG IRB). Bert has been working for IRB since 2007. In this role, Bert advises the IRB on appropriateness and regulatory aspects of a wide array of research such as FDA regulated studies, Social/Behavioral Health research, International research, Emergency Research, and research involving vulnerable subjects.

Mr. Wilkins has had an interest in research and research ethics since serving as a law clerk for the Attorney General’s Office at the University of Washington. However, Mr. Wilkins has been interested in the healthcare field most of his life. He has worked in hospitals, both in administrative and legal capacities, a healthcare consulting firm, and has done health services research.

Mr. Wilkins graduated cum laude from Seattle University School of Law in 2007. Prior to law school, he earned a Master of Healthcare Administration from the University of North Carolina – Chapel Hill with honors, and a Bachelor of Science from the University of Washington.

Share this page

Search form